Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Prudential Financial Inc.

Prudential Financial Inc. increased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 33.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 83,077 shares of the company's stock after buying an additional 20,880 shares during the period. Prudential Financial Inc. owned about 0.13% of Vera Therapeutics worth $3,513,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its position in shares of Vera Therapeutics by 116.7% in the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock valued at $857,000 after purchasing an additional 10,916 shares during the last quarter. Lord Abbett & CO. LLC grew its stake in shares of Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock worth $18,830,000 after purchasing an additional 124,197 shares in the last quarter. Barclays PLC increased its holdings in Vera Therapeutics by 94.1% in the third quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after buying an additional 41,394 shares during the last quarter. Geode Capital Management LLC raised its stake in Vera Therapeutics by 2.1% in the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock valued at $44,415,000 after buying an additional 20,223 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Vera Therapeutics by 3.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company's stock worth $15,992,000 after buying an additional 10,717 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Remove Ads

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA traded down $0.85 during midday trading on Thursday, reaching $22.74. 874,361 shares of the company were exchanged, compared to its average volume of 772,253. The stock has a market cap of $1.45 billion, a P/E ratio of -8.71 and a beta of 1.17. Vera Therapeutics, Inc. has a 1 year low of $21.24 and a 1 year high of $51.61. The stock has a fifty day simple moving average of $30.08 and a 200 day simple moving average of $38.48. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.11. On average, research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VERA. Guggenheim raised their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Wolfe Research began coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. Finally, The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $64.67.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total value of $730,450.00. Following the sale, the chief executive officer now owns 143,603 shares of the company's stock, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.70% of the stock is currently owned by corporate insiders.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.